Condition

Drug Therapy

ClinicalTrials.gov condition label

Clinical trials7

Recruiting1

Common interventions15

Lead sponsors shown7

Clinical trials

7 shown

"Extended" (Alternate Day) Antipsychotic DosingNCT04478838 · 2022-06-06

Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast CancerNCT06539559 · 2024-08-01

Effect of Chronotherapy on Blood Pressure - Time of Intake of Blood Pressure Lowering DrugsNCT05322967 · 2022-06-25

Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year OldsNCT04095104 · 2020-01-15

Comparison of Two Management Systems in Patients With Type 1 Diabetes (Pediatric SmartHome)NCT03815487 · 2018-11-19

Genetic Polymorphisms Predict Chemotherapeutic Outcomes in Patients With Metastatic Breast CancerNCT01199393 · 2010-08-01

A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR MutationsNCT01131429 · 2010-06-01

Common interventions

BevacizumabDRUG1 CisplatinDRUG1 DocetaxelDRUG1 EribulinDRUG1 ErlotinibDRUG1 Immediate Release TopiramateDRUG1 Medtronic MiniMed 670G Insulin Pump in Auto ModeDEVICE1 Medtronic MiniMed 670G Insulin Pump without Auto ModeDEVICE1 OlanzapineDRUG1 paliperidoneDRUG1 PhentermineDRUG1 Placebo for Immediate Release TopiramateDRUG1 Placebo for PhentermineDRUG1 RisperidoneDRUG1 Time of ordinary antihypertensive medication intakeOTHER1

Leading sponsors

Centre for Addiction and Mental Health1 Chinese PLA General Hospital1 Kinderkrankenhaus auf der Bult1 Peking University Cancer Hospital & Institute1 University of Colorado, Denver1 Vastra Gotaland Region1 Wang Jiayu1

Trial status mix

COMPLETED3

UNKNOWN3

RECRUITING1

Phase mix

PHASE23

NA2

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.